Sec Form 4 Filing - SCHAISON PHILIPPE @ Allergan plc - 2016-06-08

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person SCHAISON PHILIPPE 2. Issuer Name and Ticker or Trading Symbol Allergan plc [ AGN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) EVP, President Allergan Med (Last) (First) (Middle) CLONSHAUGH BUSINESS AND TECHNOLOGY PARK,, COOLOCK, CO. 3. Date of Earliest Transaction (MM/DD/YY) 06/08/2016 (Street) DUBLIN, L200000 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares, par value $0.0001 8,620 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 112.2 ( 2 ) 10/31/2023 Ordinary Shares 16,152 16,152 D Stock Option (Right to buy) $ 154.87 ( 3 ) 02/21/2024 Ordinary Shares 16,387 16,387 D Stock Option (Right to buy) $ 289.75 ( 4 ) 02/20/2025 Ordinary Shares 8,149 8,149 D Stock Option (Right to buy) $ 307.51 ( 5 ) 03/17/2025 Ordinary Shares 8,676 8,676 D Performance Based Restricted Stock Unit ( 6 ) ( 6 ) ( 6 ) Ordinary Shares 9,344 9,344 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other SCHAISON PHILIPPE CLONSHAUGH BUSINESS AND TECHNOLOGY PARK, COOLOCK, CO. DUBLIN, L200000 EVP, President Allergan Med Signatures /s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting Person 06/08/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc. ( 2 )Vests in four equal annual installments commencing on the first anniversary of the grant date (October 31, 2013). ( 3 )Vests in four equal annual installments commencing on the first anniversary of the grant date (February 21, 2014). ( 4 )Vests in four equal annual installments commencing on the first anniversary of the grant date (February 20, 2015). ( 5 )Vests in five equal annual installments commencing on the first anniversary of the grant date (March 17, 2015). ( 6 )Represents performance-based restricted share units ("PSUs") which will vest as to one-third of the total grant on each of December 31, 2017, 2018 and 2019, subject to the achievement by the Issuer of certain performance criteria. Each PSU represents a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.